9 minutes read

When international patients seek a Chinese specialist’s opinion, a concrete choice comes up early: work with a single specialist, or convene a multidisciplinary team (MDT) consultation? The two formats differ in price by several multiples and carry meaningfully different clinical value. This article walks through when MDT’s additional investment is worth it, when a single expert is enough, and how to judge which one fits your specific case.

The Fundamental Difference Between the Two Formats

Single Expert Consultation Your records are reviewed by one specialist from a single department — a chief of hepatobiliary surgery, an interventional cardiologist, an orthopedic chief. The specialist provides deep input within their specialty and tells you “this is how our department would handle this.”

Multidisciplinary Team (MDT) Consultation Your records are reviewed and discussed by multiple specialists across relevant departments simultaneously. For an oncology case, an MDT might include:

  • Medical oncologist
  • Surgical specialist (hepatobiliary, thoracic, etc.)
  • Radiation oncologist
  • Radiologist
  • Pathologist
  • Interventional specialist
  • When appropriate: rehabilitation, nutrition, psychology

5–10 specialists examine the same case at the same time, deliberate collectively, and issue an integrated opinion — instead of you running specialty-by-specialty seeking opinions individually.

How MDT Developed in China and Its Institutional Status

China’s National Health Commission established MDT as a core oncology care model starting in 2017 [1], requiring pilot hospitals to establish cross-departmental MDT teams and dedicated MDT offices, led by a designated vice-president. As of 2026, MDT has become standard practice in oncology, cardiovascular, complex trauma, rare disease, and other specialty departments at major Chinese Tier-3A hospitals.

International benchmarks for context:

  • NCCN (National Comprehensive Cancer Network, US) mandates MDT decision-making for pancreatic cancer and several other cancers [2]
  • NICE QS78 (UK National Institute for Health and Care Excellence) mandates MDT decision-making for all newly diagnosed sarcoma patients [3]
  • 2025 ESC/EACTS Valvular Heart Disease Guidelines: complex valve disease, TAVI, and TEER decisions must be made by a Heart Team (multidisciplinary cardiac team) [4]

In other words, MDT isn’t a Chinese “add-on service” — it’s the international standard of care for specific conditions. China’s MDT system is aligning with international practice, not lagging behind it.

Which Conditions Should Use MDT

Strongly recommended for MDT:

Category Specific Situations
Complex oncology Pancreatic cancer, esophageal cancer, hepatobiliary cancers, sarcomas, neuroendocrine tumors, recurrent/metastatic cancers, borderline resectable cases, neoadjuvant treatment decisions
Complex cardiac disease Complex valvular disease, TAVI/TEER decisions, complex congenital heart disease, surgical decisions for heart failure
Complex orthopedics All sarcomas, complex polytrauma, re-excision decisions after unplanned excision
Rare disease Undiagnosed complex syndromes, multi-system involvement, cases where home country diagnosis is contested
Cross-specialty treatment Cases requiring neoadjuvant chemotherapy + surgery + radiation + targeted therapy combinations
Second opinion that differs from home country plan Existing home country plan needs validation

Single expert consultation is usually sufficient for:

  • Routine surgery (joint replacement, cataract, elective appendectomy, IVF, etc.)
  • Single-specialty common cases (such as detailed surgical technique discussions, conservative treatment details)
  • Cases where diagnosis and plan are already established and only surgical or interventional technique discussion is needed
  • Chronic disease management, follow-up consultations
  • Psychological evaluation, nutritional counseling

Hard Evidence That MDT Improves Outcomes

International medical literature has accumulated substantial evidence on MDT’s clinical impact:

  • Esophageal cancer: MDT discussion is associated with median survival extending from 4.5 months to 10.7 months (HR 0.72) [5]
  • Comprehensive second opinion value (Memorial Sloan Kettering US-based study): A 120-case second-opinion study at MSK in the US found that even when the original diagnosis was confirmed, treatment plans after MDT review were often adjusted to lower-intensity versions, saving an average of approximately $15,000 USD per patient with equal or better quality of life and survival [6]. Note that this study comes from a US institution; the cost-savings comparison reflects US cancer treatment economics, but the underlying clinical insight (MDT often produces less aggressive but equally effective plans) applies internationally.
  • Sarcoma diagnostic accuracy: MDT raises preoperative diagnostic accuracy to approximately 95% [7]

The practical takeaway for international patients: MDT is not just “more opinions” — it’s “a more rational plan” — it helps you avoid unnecessary or excessive treatment, ultimately saving money, time, and quality of life.

Specific MDT Capabilities at Top Chinese Hospitals

Peking Union Medical College Hospital (PUMC) [8]

  • Difficult and Rare Disease Consultation Center covers 60 departments and 800+ senior specialists
  • Rare disease MDT convenes every Thursday at noon
  • Demonstrated impact: reduced rare disease diagnostic timeline from an average of 4 years to approximately 4 weeks
  • Multispecialty MDTs are institutionalized: complex pain, palliative care, hemophilia, and rare disease combined clinics

Sun Yat-sen University Cancer Center (SYSUCC) [9]

  • Established China’s first breast cancer MDT in 1997 — one of the earliest MDT teams in China
  • Expanded to 17 single-disease MDT teams, each led by a designated Chief Specialist
  • A single MDT session typically includes 6–10 multidisciplinary specialists
  • The gastric cancer MDT team won the national MDT competition

Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS)

  • Established China’s earliest lymphoma MDT in the 1970s
  • Telemedicine Center provides both single-specialty and multidisciplinary remote consultations with formal consultation reports

Fudan University Shanghai Cancer Center (FUSCC) [10]

  • Established its breast MDT in 2002; the team treats 15,000 cases per year
  • Breast cancer 5-year survival rate of 93.6% (on par with top international centers)
  • Established China’s first urologic oncology MDT platform in 2005

Shanghai Ruijin Hospital [11]

  • Established a CNS oncology MDT in 2015 (neurosurgery + radiotherapy + gamma knife + imaging + pathology + endocrinology + neurology + gynecology)
  • Cumulative experience: 1,000+ complex case analyses

All of the above hospitals offer MDT access to international patients, either directly through the hospital’s IMD or through coordination services like MedCareInChina, with remote or in-person formats available.

A Real Case Example: How MDT Changed a Pancreatic Cancer Decision

To illustrate concretely how MDT changes treatment decisions, here is a representative case (anonymized, structured around a real pattern MedCareInChina has coordinated multiple times):

Patient profile: 62-year-old male from Germany, diagnosed with pancreatic head adenocarcinoma, 3.5 cm mass, abutting the portal vein.

Home country plan (Germany, single specialist): A senior hepatobiliary surgeon recommended immediate Whipple procedure (pancreaticoduodenectomy), with adjuvant chemotherapy to follow if margins were positive. Estimated total cost in Germany: €85,000. Patient sought a second opinion in China.

Chinese MDT setup: Patient requested an MDT through MedCareInChina. The MDT was convened at a leading Chinese Tier-3A hospital and included:

  • Hepatobiliary surgeon (chief)
  • Medical oncologist
  • Radiation oncologist
  • Interventional radiologist
  • Pathologist
  • Diagnostic radiologist

MDT discussion outcome:

  1. Pathology re-review: The Chinese pathologist confirmed the adenocarcinoma diagnosis but identified additional features suggesting moderate differentiation (the original report had not specified grade)
  2. Imaging re-review: The radiologist identified that the portal vein contact was greater than 180 degrees — putting the case in the “borderline resectable” category (BR-PDAC) by NCCN criteria
  3. NCCN-aligned recommendation: Based on this re-classification, the MDT recommended neoadjuvant chemotherapy (FOLFIRINOX × 4 cycles) followed by restaging and consideration of surgery — rather than immediate surgery
  4. Rationale: Studies show neoadjuvant therapy in borderline resectable pancreatic cancer significantly improves R0 resection rates and long-term survival compared with upfront surgery

Patient’s decision and outcome:

  • Patient accepted the MDT recommendation
  • Completed 4 cycles of FOLFIRINOX in Germany (local availability)
  • Restaging showed tumor regression and reduced vascular involvement
  • Returned to China for surgery 5 months later; achieved R0 resection
  • Recovery on schedule with adjuvant therapy continuing in Germany

Cost comparison:

  • Original German plan (immediate Whipple + adjuvant chemo): ~€85,000
  • Adjusted path (neoadjuvant chemo in Germany + Whipple in China + adjuvant in Germany): ~€55,000 (Germany) + ~$30,000 (China) ≈ €83,000 total

Key value of MDT: in this case, the MDT didn’t necessarily save money — it improved the clinical plan. By correctly categorizing the case as borderline resectable and recommending neoadjuvant therapy, the MDT likely improved the R0 resection rate and long-term survival. Without MDT, the patient would have gone straight to surgery and faced a meaningfully higher risk of incomplete resection.

Pricing

MedCareInChina’s consultation pricing:

Service Type Price (USD) Includes
Single Expert Consultation $800 (all-inclusive) Complete consultation or written opinion from one specialist
MDT Consultation $1,000 per expert Joint consultation by multiple specialists from different departments + integrated written opinion

Typical MDT combinations and total cost:

Case Type Typical Specialist Composition MDT Total (USD)
Early-to-mid-stage cancer (e.g., early lung cancer) 3 specialists (medical oncology + thoracic surgery + radiation oncology) $3,000
Complex or late-stage cancer (e.g., pancreatic cancer) 4–5 specialists (surgery + medical oncology + radiation + pathology + imaging) $4,000–$5,000
Rare disease / multi-system involvement 5–7 specialists (multispecialty combined) $5,000–$7,000
Complex valvular disease Heart Team 4 specialists (cardiology + cardiac surgery + imaging + anesthesia) $4,000
Complex orthopedic / sarcoma 4–5 specialists (orthopedic surgery + medical oncology + radiation + pathology) $4,000–$5,000

A Decision Framework: How to Choose

Choose Single Expert ($800) when:

  • Diagnosis is established and the treatment path is clear
  • You need deep input from one specialty only
  • You’ve already had an MDT (in your home country or earlier in China) and need a single-specialty follow-up discussion
  • Time and budget are tight

Choose MDT ($3,000–$5,000) when:

  • Diagnosis is unclear or the home country diagnosis is contested
  • The treatment plan requires multiple specialties (such as oncology with neoadjuvant + surgery + radiation)
  • Borderline resectable, recurrent/metastatic, or multi-line treatment failure
  • Rare disease or complex syndrome
  • The home country’s recommendation gives you pause (feels too aggressive or too conservative)
  • You’re choosing between 2–3 Chinese hospitals — use MDT to compare integrated opinions across multiple centers

What You Receive from an MDT

A complete Chinese MDT typically delivers:

  1. Multidisciplinary Consultation Record: each of the 5–10 specialists’ individual opinions + collective discussion conclusion
  2. Consensus treatment plan: the team-recommended plan with specific steps, timeline, expected outcomes
  3. Alternative plan comparison: if multiple plans are feasible, the comparative trade-offs of each
  4. Recommended next steps: whether additional testing is needed, whether on-site treatment is advised, expected treatment timeline
  5. Recommended hospital and team: if on-site treatment is recommended, the specific hospital, department, and team
  6. Budget estimate: full estimated cost in China for treatment (surgery, inpatient, supporting tests, follow-up)

Five Scenarios Where International Patients Most Need MDT

Scenario 1 · “Neoadjuvant treatment vs. immediate surgery” decision in oncology For borderline resectable pancreatic cancer, liver cancer, esophageal cancer — whether to start with neoadjuvant chemotherapy or proceed directly to surgery is a classic MDT decision.

Scenario 2 · Treatment pathway selection for recurrent/metastatic cancer A single specialty often can’t judge between aggressive treatment (multi-line chemo + targeted + immunotherapy) and comprehensive management (symptom control + quality of life). MDT integrates the surgical, oncology, radiation, and palliative perspectives.

Scenario 3 · Diagnosis of rare disease or complex syndromes Symptoms crossing multiple systems (autoimmune disease affecting multiple organs, fever of unknown origin, rare genetic syndromes) — a single specialty rarely sees the full picture, and MDT is the core solution.

Scenario 4 · Complex valvular disease or congenital heart disease TAVI or SAVR? Which valve type? These require a Heart Team (cardiology + cardiac surgery + imaging + anesthesia) for integrated decision-making.

Scenario 5 · Home country recommendation differs significantly from your expectations Your home country says “not operable” but you don’t accept that; or your home country recommends an aggressive option and you want to know if there’s a more conservative alternative. MDT provides an independent, multi-perspective third-party view.

Common Questions

Is MDT always better than Single Expert? No. For cases with clear diagnosis and a clear treatment path, Single Expert is more efficient. MDT’s value is for complex, cross-specialty, or decision-uncertain cases.

Can MDT be conducted remotely? Yes. All major Chinese Tier-3A hospitals have remote MDT capability. MedCareInChina offers remote MDT services — Chinese specialists convene via video, with you participating in real-time from your home country (with bilingual interpretation).

How important is the MDT written opinion? Very important. A formal MDT written opinion contains 5–10 specialists’ signed opinions + a collective consensus — this is a high-weight clinical decision document by international standards, and your home physician will typically take it seriously.

If I’ve already had an MDT in my home country, do I still need one in China? Depends on the situation:

  • If your home country MDT’s conclusion aligns with what you want → not necessarily
  • If you want to learn whether China offers different treatment options (CAR-T, proton/heavy-ion, complex surgery) → a Chinese MDT has independent value
  • If you’ve decided to come to China but are choosing between hospitals → a Chinese MDT helps you choose the right hospital

What language is MDT conducted in? English-Chinese bilingual by default. The video consultation has a medical interpreter present; the written opinion is delivered in both Chinese and English.

After the MDT, can on-site surgery in China be arranged directly? Yes. The MDT typically recommends a specific hospital and team, and MedCareInChina coordinates the visa, flights, accommodation, and on-site logistics for the next phase.

Bottom Line

Single Expert ($800): diagnosis is established, single-specialty path, efficiency is the priority.

MDT ($3,000–$5,000): complex, cross-specialty, diagnosis unclear, or decision-uncertain — especially oncology, complex cardiac disease, rare disease, complex orthopedics.

The core value of MDT: not “more specialists costing more money” but a more rational plan from multiple perspectives — international data shows MDT can help patients avoid over-treatment, save costs, and improve survival.

For complex cases worth traveling to China for treatment, MDT is almost always a worthwhile investment — relative to total treatment costs in the tens to hundreds of thousands of dollars, the $3,000–$5,000 MDT investment is what ensures your money goes to the optimal plan.

If you’re unsure whether your case fits a Single Expert or an MDT, send us a brief case description. MedCareInChina will recommend based on your specific situation.

→ Send your case to hello@medcareinchina.com

See Service & Refund Policy and Medical Disclaimer for service boundaries.

Sources

  1. National Health Commission Oncology MDT Pilot Framework 2018 — Based on the Further Improving Medical Services Action Plan (2018–2020) (国卫医发〔2017〕73 号), establishing nationwide oncology MDT pilots. https://www.cn-healthcare.com/article/20180828/content-507439.html
  2. NCCN Pancreatic Cancer Guidelines MDT Requirement — The U.S. National Comprehensive Cancer Network (NCCN) mandates pancreatic cancer decisions be made by an MDT including radiology, gastroenterology, surgery, medical oncology, radiation oncology, endocrinology, and pathology. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505812/
  3. NICE QS78 Sarcoma MDT Requirement — UK National Institute for Health and Care Excellence: all newly diagnosed sarcoma patients must be decided by MDT. https://www.nice.org.uk/guidance/qs78/chapter/quality-statement-2-multidisciplinary-teams-for-sarcoma
  4. 2025 ESC/EACTS Valvular Heart Disease Guidelines Heart Team Requirement — European Society of Cardiology and European Association for Cardio-Thoracic Surgery: complex valvular disease, TAVI, TEER decisions must be made by a Heart Team. https://academic.oup.com/eurheartj/article/46/44/4635/8234488
  5. Esophageal Cancer MDT Improves Survival — Median survival extended from 4.5 months to 10.7 months (HR 0.72). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11518921/
  6. Memorial Sloan Kettering MDT Second Opinion Value Study (US-based research) — 120-case second-opinion study at MSK in the United States found that even when diagnosis was confirmed, treatment plans were often adjusted to lower-intensity versions, saving an average of approximately $15,000 USD per patient with equal or better quality of life and survival. Note: cost figures reflect US healthcare economics; the underlying clinical insight applies internationally. https://www.mskcc.org/news/getting-second-opinion-for-cancer-new-study-finds-it-can-lower-costs-and-improve-quality-of-life-and-survival
  7. Sarcoma MDT Diagnostic Accuracy Improvement — MDT raises preoperative diagnostic accuracy to approximately 95%. https://pubmed.ncbi.nlm.nih.gov/36556299/
  8. PUMC Difficult and Rare Disease MDT — 60 departments, 800+ senior specialists. Rare disease MDT reduced diagnostic timeline from 4 years to approximately 4 weeks. https://www.pumch.cn/detail/30660.html ; https://ims.pumch.cn/detail/35846.html
  9. Sun Yat-sen University Cancer Center MDT — 17 single-disease MDT teams; established China’s first breast cancer MDT in 1997. https://www.sysucc.org.cn/department/introduction/44
  10. Fudan Cancer Center Breast MDT — Established 2002; treats 15,000 cases per year; breast cancer 5-year survival rate of 93.6%. http://health.people.com.cn/n1/2018/1010/c421589-30333003.html
  11. Shanghai Ruijin Hospital CNS Oncology MDT — Established 2015; cumulative 1,000+ complex case analyses. https://www.brainmed.com/info/detail?id=19515